Physician profile
Hrudya Abraham
NPI 1497135750
$1,813.72
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.49 · 2021: $487 · 2022: $841 · 2023: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $502.04 | 2020-2023 | Otezla, Enbrel |
| Abbvie INC. | $279.14 | 2021-2023 | Rinvoq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.93 | 2021-2023 | Ofev |
| Sanofi-Aventis U.S. LLC | $202.53 | 2021-2022 | |
| Ucb, INC. | $122.79 | 2022-2023 | Cimzia |
| Lilly USA, LLC | $114.09 | 2021-2023 | Taltz |
| Janssen Biotech, INC. | $90.74 | 2022-2023 | Tremfya |
| Novartis Pharmaceuticals Corporation | $83.01 | 2022-2023 | |
| Glaxosmithkline, LLC. | $73.13 | 2021-2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $38.57 | 2023 | Saphnelo |
| Pfizer INC. | $37.10 | 2020-2021 | |
| Organon LLC | $32.28 | 2023 | Renflexis |
| Actelion Pharmaceuticals US, INC. | $20.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hrudya Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.